ExploreInterventionIntrathecal chemotherapy
Intervention

Intrathecal chemotherapy

Also known as: Intrathecal chemotherapy alone (methotrexate, cytarabine, hydrocortisone, cytarabine liposome combinations) for CNS leukemia treatment, without cranial radiation
3 findings 1 paper 3 related entities View in graph →

Related entities

conditions
outcomes
studys

Findings (27)

None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%
None
improvement

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Size: 51% vs. 18%

Papers (1)